Publications

PEER REVIEWED PRIMARY RESEARCH ARTICLE

Salji M, Hendry J, Patel A, Ahmad I, Nixon C, Leung HY.  “Peri-prostatic Fat Volume Measurement as a Predictive Tool for Castration Resistance in Advanced Prostate Cancer”.  European Urology Focus 2017; http://dx.doi.org/10.1016/j.euf.2017.01.019

Ahmad I, Mui E, Galbraith L, et al. “Sleeping Beaty screen reveals Pparg activation in metastatic prostate cancer”. PNAS 2016; doi: 10.1073/pnas.1601571113

Tan WS, Lamb BW, Tan MY, Ahmad I, et al. “In-depth analysis of complications following Robot-assisted radical cystectomy with intracorporeal urinary diversion”. European Urology Focus 2016; In Press

Lamb BW, Tan WS, Eneje P, Bruce D, Jones A, Ahmad I, et al. “Benefits of robotic cystectomy with intracorporeal diversion for patients with low cardiorespiratory fitness: A prospective cohort study”. Urol Oncol 2016; In Press

Choudhury Y, Yang Z, Ahmad I, Salt I, Leung HY. “AMP-activated kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer”. Oncoscience 2014; 1(6): 446-456.

Foth M, Ahmad I, van Rhijn BWG, van der Kwast T, Bergman AM, King, Louise, Ridgway R, Leung HY, Fraser S, Sansom OJ, Iwata T. “Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice”. J Pathol 2014; 233: 148-158.

Rajan P, Sudbery IM, Villasevil MEM, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, Ponting CP, Heger A, McMenemin RM, Pedley ID, Leung HY. “Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy”. European Urology 2014; 66(1): 32-9.

 Stockley J, Vilasevil ME, Nixon C, Ahmad I, Leung HY, Rajan P. “The RNA-binding protein hnRNPA2 regulates β-Catenin protein expression and is overexpressed in prostate cancer”. RNA Biology 2014; 11(6): 755-765.

 Ahmad I, Kalna G, Ismail M, Birrell F, Asterling S, McCartney E, Greene D, Davies J, Leung HY. “Prostate Gland Lengths and Iceball Dimensions Predict Micturition Functional Outcome Following Salvage Prostate Cryotherapy in Men with Radiation Recurrent Prostate Cancer”. PLOS One 2013; 10.1371/journal.pone.0069243

Zhang T, Watson DG, Wang L, Abbas M, Murdoch L, Bashford L, Ahmad I, Lam NY, Ng ACF, Leung HY. “Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery”. PLOS One 2013; 10.1371/journal.pone.0065880.

Patel R, Gao M, Ahmad I, Fleming J, Norman J, Sansom OJ, McKie AB, Singh LB, Seywright M, Barnetson RJ, Edwards J, Leung HY. “Sprouty2 expression governs prostate cancer progression by regulating cellular distribution of PTEN”. Journal of Clinical Investigation 2013; 123(3): 1157-75.

 Ahmad I, Singh LB, Yang ZH, Kalna G, Fisher G, Cooper C, Cuzick J, Berney DM, Møller H, Scardino P, Leung HY. “Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer”. British Journal of Cancer 2013; 108(1):149-54.

Yang Z, Laird A, Monaghan A, Seywright M, Ahmad I, Leung HY. “Incidental seminal vesicle amyloidosis observed in diagnostic prostate biopsies-are routine investigations for systemic amyloidosis warranted?” Asian Journal of Andrology 2013; 15(1):149-51.

McCall P, Bennett L, Ahmad I, Mackenzie LM, Forbes IW, Leung HY, Sansom OJ, Orange C, Seywright M, Underwood MA, Edwards J. “NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression”. British Journal of Cancer 2012; 107(9): 1554-63.

Gao M, Patel R, Ahmad I, Fleming J, Norman J, Sansom OJ, Leung HY. “SPRY2 loss enhances ErbB trafficking and PI3K/AKT signaling to drive human and mouse prostate carcinogenesis”. EMBO Molecular Medicine 2012; 4(8): 776-90.

Ahmad I, Small DR, Krishna NS, Akhtar MN, Leung HY. “Prostate Cancer Incidence in Patients on 5α-Reductase Inhibitors for Lower Urinary Tract Symptoms:  A 14 Year Retrospective Study”. BJMSU 2012; 5(4): 179-83.

 Ahmad I, Patel R, Singh LB, Nixon C, Seywright M, Barnetson RJ, Muller WJ, Edwards J, Sansom OJ, Leung HY. “HER2 overcomes PTEN (loss) induced Senescence to cause Aggressive Prostate Cancer”. PNAS 2011; 208(39): 16392-97.

Armstrong K, Ahmad I, Kalna G, Tan S, Edwards J, Robson CN, Leung HY. “Upregulated FGFR1 expression is associated with the transition of hormone naive to castrate resistant prostate cancer”. British Journal of Cancer 2011; 105(9): 1362-69.

 Ahmad I, Singh LB, Morris CA, Taketo MM, Wu XR, Leung, Sansom OJ, Iwata T. “K-Ras and β-Catenin mutations cooperate with the FGFR3 mutations to promote tumorigenesis in the skin and lung, but not in the bladder”. Disease Models & Mechanisms 2011; 4(4): 548–55.

 Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, Leung HY, Sansom OJ. “Ras mutation cooperates with β-catenin activation to drive bladder tumorigenesis”.       Cell Death and Disease 2011; 2(1): e124.

Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo MM, Wu X-R, Leung HY, Sansom OJ. “β-Catenin Activation Synergises with PTEN Loss to Cause Bladder Cancer Formation”. Oncogene 2011; 30: 178-89.

 Tan S, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, Barnetson RJ, Edwards J, Leung HY. “GRP78 Up-Regulation is Associated with Androgen Receptor Status, Hsp70-Hsp90 Client Proteins and Castrate Resistant Prostate Cancer”. Journal of Pathology 2011; 223(1): 81-7.

Ramsay AK, McCracken SRC, Soofi M, Fleming J, Yu AX, Ahmad I, R Morland R, L Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marquez R, Keller E and Leung HY, “ERK5 signalling in prostate cancer promotes an invasive phenotype”. British Journal of Cancer 2011; 104(4): 664-72.

Nelson AW#, Ahmad I#, Pickard RS, Leung HY. “The new BAUS section of Academic Urology: A survey of the urological community”. BJMSU 2009; 2(4): 147-53.

 Ahmad I, Sarath Krishna N, Small DR, Conn IG. “Aetiology and management of acute female urinary retention”. BJMSU 2009; 2(1): 27-33.

Ahmad I, Sarath Krishna N, Meddings RN. “Role of Hydrodistension and Intravesical Instillation of Cystistat for Resistant Interstitial Cystitis”. International Journal of Urogynaecology 2008; 19(4): 543-6.

Ahmad I, Sarath Krishna N, Clark R, Al-Saffar N, Nairn R.       “Interval Development of Testicular Carcinoma in Patients with Previously Demonstrated Testicular Microlithiasis”. International Journal of Urology and Nephrology 2007; (39) 4: 1177-81.

 Ahmad I, Sarath Krishna N, Meddings RN. “Role of EMLA Cream in Biopsy and Excision of Penile Lesions”. Annals of the Royal College of Surgeons of England 2007; 89: 73.

Ahmad I, Konduru S. “Changes in Functional Status whilst awaiting primary knee Arthroplasty“. The Surgeon 2007; 5(5): 266-68.

Ahmad I, Adlard P, Duncan P, Bunyan DJ, Harvey J, Tolmie J, Donaldson MDC. “A Novel Mutation of DAX-1 with an Atypical Presentation of X-linked Adrenal Hypoplasia Congenita”. Hormone Research 2007; 68: 32-7.

 Ahmad I, Patil S. “Isolated Deep Peroneal Nerve Palsy in Association with Primary Total Hip Arthroplasty”. Clinical Anatomy 2007; 20(6): 703-05.

 

REVIEW ARTICLES

Maitra NU, Ahmad I.  “Is a single screening round sufficient to detect all high-risk prostate cancers?—lessons learned from the European Randomized Study of Screening for Prostate Cancer Study (Editorial)”. Journal of Xiangya Medicine 2017; doi: 10.21037/jxym.2017.02.04  

Salji M, Ahmad I, Winchester C.  “Non-clinical research – laboratory based”.  Journal of Clinical Urology 2016; 9(6).

Ahmad I, Crosbie RA, Ramsay AK, Nalagatla SK.       “Comparison of Urologist and Radiologist gained Percutaneous Renal Access during PCNL: A Review”. Journal of Clinical Urology 2014; 7: 20-24.

 Barry L, Ahmad I, Pokrovska T, Rajan P.       “Current management options for the small renal mass in a solitary kidney”. Scott Med J 2012; 57(3): 157-62.

 Ahmad I, Sansom OJ, Leung HY. “Exploring molecular genetics of bladder cancer: lessons learned from mouse models”. Disease Models & Mechanisms 2012; 5(3): 323-32.

 Ahmad I, Iwata T, Leung HY. “Mechanisms of FGFR-mediated carcinogenesis”. Biochimica Et BiophysicaI Acta – Molecular Cell Research 2012; 1823(4): 850-60.

 Ahmad I, Sansom OJ. ”Today’s research, tomorrow’s therapies”. Future Oncology 2010; 6(7): 1095-97.

Ahmad I, Sansom OJ, Leung HY. “The role of murine models of prostate cancer in drug target discovery and validation”. Expert Opinion on Drug Discovery 2009; 4(8): 879-88.

 Ahmad I, OJ Sansom, HY Leung. “Advances in Mouse Models of Prostate Cancer”. Expert Reviews in Molecular Medicine 2008; 10: e16.

Ahmad I, Sarath Krishna N. “Keratinising Squamous Metaplasia of the Bladder”. Urologica Internationalis 2008; 81: 247-51.

Ahmad I, Small DR, Granitsiotis P.       “The Role of Ultrasound for the Measurement of Bladder Volume.” Urology News 2008; 12(2): 10-13.

Ahmad I, Sarath Krishna N. “Hemospermia”. Journal of Urology 2007; 177: 1613-18.

Ahmad I, Granitsiotis P. “Urological Follow Up of Adult Spina Bifida Patients”. Neurourology and Urodynamics 2007; 26(7): 978-80.

# Joint 1st Authors

 

CASE REPORTS

Majumdar P, McSorley S, Ahmad I, Dunn IB. “Xanthogranulomatous Prostatitis Presenting as a Prostatic Abscess: Case Report and Review of Literature”. World Journal of Nephrology and Urology 2013; 2(1): 25-8.

Barry L, Baxter G, Pitchamuthu H, Crooks JE, Rajan P, Ahmad I. “Aggressive bladder leiomyosarcoma in a patient receiving tamoxifen therapy”. Journal of Clinical Urology 2013; 6(5): 327-9 .    

 

PUBLISHED ABSTRACTS

 Ahmad I, Gao M, Patel R, Leung HY. “SPRY2 loss enhances ErbB trafficking and PI3K/AKT signaling to drive human and mouse prostate carcinogenesis”. BJU International 2012; 109 (S7): 29.

Ahmad I, Armstrong K, Robson CN, Leung HY. “Upregulated FGFR1 expression is associated with the transition of hormone naive to castrate resistant prostate cancer”. BJU International 2012; 109 (S7): 29.

Ahmad I, Sansom OJ, Leung HY. “HER2 overcomes PTEN-loss induced cellular senescence to cause aggressive prostate cancer”. BJS 2011; 98(S1): 47.

Ahmad I, Sarath Krishna N, Small DR, Conn IG.       “Management of Female Urinary Retention: An 11 Year Experience”. BJU International 2008; 101(S5): 29.

 Ahmad I, Sarath Krishna N, Small DR, Morrison L, Akhtar MN. “CT Urogram as an Initial Investigation in Frank Haematuria”. BJU International 2007; 99(S4): 22.

 Ahmad I, Sarath Krishna N, Clark R, Al-Saffar N, Nairn R.       “Interval Development of Testicular Carcinoma in Patients with Previously Demonstrated Testicular Microlithiasis”. BJU International 2007; 99(S4): 51.

Ahmad I, Sarath Krishna N, Small DR, Morrison L, Akhtar MN. “Prostate Cancer Incidence in Patients on Finasteride for Lower Urinary Tract Symptoms”. J. Urol 2007; 177(S4): 75.

 Ahmad I, Sarath Krishna N, Clark R, Al-Saffar N, Nairn R.       “Interval Development of Testicular Carcinoma in Patients with Previously Demonstrated Testicular Microlithiasis”. J. Urol 2007; 177(S4): 400.

 Ahmad I, Sarath Krishna N, Meddings RN. “Role of Hydrodistension and Intravesical Instillation of Cystistat for Resistant Interstitial Cystitis”. J. Urol 2007; 177(S4): 47.

 Ahmad I, Hilmy M, Small DR, Conn IG. “Is urethroplasty a feasible long-term solution for urethral stricture?”   J. Urol 2007; 177(S4): 13-14.

 Ahmad I, Sarath Krishna N, Small DR, Morrison L, Akhtar MN. “Prostate Cancer Incidence in Patients on Finasteride for Lower Urinary Tract Symptoms”. European Urology 2007; 6(S2): 177.

 Ahmad I, Sarath Krishna N, Meddings RN. “Role of Hydrodistension and Intravesical Instillation of Cystistat for Resistant Interstitial Cystitis”. BJU International 2006; 97(S3): 34.

Advertisements